Tonmya

Overview

cyclobenzaprine

muscle relaxant

• CYP1A2 substrate
• anticholinergic effects
• CNS depression
• lowers seizure threshold
• serotonergic effects

• add MAO inhibitor to Interaction Check if recent (14 days) use

Contraindicated

• isocarboxazid
Tonmya (cyclobenzaprine)

+

isocarboxazid

1 interaction

Contraindicated

cyclobenzaprine + isocarboxazid

contraindicated; may initiate cyclobenzaprine 14 days after isocarboxazid D/C; may initiate isocarboxazid start dose 7 days after cyclobenzaprine D/C and titrate after x1wk: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment, hyperpyretic crisis, seizures, severe constipation, paralytic ileus, urinary retention (additive effects)

• phenelzine
Tonmya (cyclobenzaprine)

+

phenelzine

1 interaction

Contraindicated

cyclobenzaprine + phenelzine

contraindicated w/in 14 days of phenelzine use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment, hyperpyretic crisis, seizures, severe constipation, paralytic ileus, urinary retention (additive effects)

• potassium chloride
Tonmya (cyclobenzaprine)

+

potassium chloride

1 interaction

Contraindicated

cyclobenzaprine + potassium chloride

contraindicated w/ solid potassium formulations; consider alternative, incl. liquid potassium formulations: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• potassium citrate
Tonmya (cyclobenzaprine)

+

potassium citrate

1 interaction

Contraindicated

cyclobenzaprine + potassium citrate

contraindicated w/ solid potassium formulations; consider alternative, incl. liquid potassium formulations: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• rasagiline
Tonmya (cyclobenzaprine)

+

rasagiline

1 interaction

Contraindicated

cyclobenzaprine + rasagiline

contraindicated w/in 14 days of rasagiline use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• safinamide
Tonmya (cyclobenzaprine)

+

safinamide

1 interaction

Contraindicated

cyclobenzaprine + safinamide

contraindicated w/in 14 days of safinamide use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• selegiline
Tonmya (cyclobenzaprine)

+

selegiline

1 interaction

Contraindicated

cyclobenzaprine + selegiline

contraindicated w/in 14 days of selegiline use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• selegiline transdermal
Tonmya (cyclobenzaprine)

+

selegiline transdermal

1 interaction

Contraindicated

cyclobenzaprine + selegiline transdermal

contraindicated w/in 14 days of selegiline transdermal use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment, hyperpyretic crisis, seizures (additive effects)

• tranylcypromine
Tonmya (cyclobenzaprine)

+

tranylcypromine

1 interaction

Contraindicated

cyclobenzaprine + tranylcypromine

contraindicated w/in 14 days of tranylcypromine use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment, severe constipation, paralytic ileus, urinary retention (additive effects)

Avoid/Use Alternative

• 5-HTP
Tonmya (cyclobenzaprine)

+

5-HTP

1 interaction

Avoid/Use Alternative

cyclobenzaprine + 5-HTP

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• aclidinium inhaled
Tonmya (cyclobenzaprine)

+

aclidinium inhaled

1 interaction

Avoid/Use Alternative

cyclobenzaprine + aclidinium inhaled

avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

• aldesleukin
Tonmya (cyclobenzaprine)

+

aldesleukin

1 interaction

Avoid/Use Alternative

cyclobenzaprine + aldesleukin

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, seizures (additive effects)

• alfentanil
Tonmya (cyclobenzaprine)

+

alfentanil

1 interaction

Avoid/Use Alternative

cyclobenzaprine + alfentanil

use alternative or monitor BP, resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• almotriptan
Tonmya (cyclobenzaprine)

+

almotriptan

1 interaction

Avoid/Use Alternative

cyclobenzaprine + almotriptan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• amifampridine
Tonmya (cyclobenzaprine)

+

amifampridine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• amitriptyline
Tonmya (cyclobenzaprine)

+

amitriptyline

1 interaction

Avoid/Use Alternative

cyclobenzaprine + amitriptyline

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects, incl. hyperthermia (additive effects)

• amoxapine
Tonmya (cyclobenzaprine)

+

amoxapine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + amoxapine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects (additive effects)

• amphetamine
Tonmya (cyclobenzaprine)

+

amphetamine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + amphetamine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. amphetamine start dose: combo may incr. risk of serotonin syndrome (additive effects)

• benztropine
Tonmya (cyclobenzaprine)

+

benztropine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + benztropine

consider alternative: combo may incr. risk of life-threatening anticholinergic adverse effects, incl. constipation, paralytic ileus, hyperthermia (additive effects)

• black cohosh
Tonmya (cyclobenzaprine)

+

black cohosh

1 interaction

Avoid/Use Alternative

cyclobenzaprine + black cohosh

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• bromocriptine
Tonmya (cyclobenzaprine)

+

bromocriptine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + bromocriptine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• buprenorphine
Tonmya (cyclobenzaprine)

+

buprenorphine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + buprenorphine

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• buspirone
Tonmya (cyclobenzaprine)

+

buspirone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + buspirone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• butalbital
Tonmya (cyclobenzaprine)

+

butalbital

1 interaction

Avoid/Use Alternative

cyclobenzaprine + butalbital

avoid combo: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• butorphanol
Tonmya (cyclobenzaprine)

+

butorphanol

1 interaction

Avoid/Use Alternative

cyclobenzaprine + butorphanol

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• carbamazepine
Tonmya (cyclobenzaprine)

+

carbamazepine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + carbamazepine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• citalopram
Tonmya (cyclobenzaprine)

+

citalopram

1 interaction

Avoid/Use Alternative

cyclobenzaprine + citalopram

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• clomipramine
Tonmya (cyclobenzaprine)

+

clomipramine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + clomipramine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, seizures, serotonin syndrome, anticholinergic adverse effects (additive effects)

• clonidine
Tonmya (cyclobenzaprine)

+

clonidine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + clonidine

if ADHD use, avoid combo; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clozapine
Tonmya (cyclobenzaprine)

+

clozapine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + clozapine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, seizures, life-threatening anticholinergic adverse effects, incl. constipation, paralytic ileus (additive effects)

• cocaine
Tonmya (cyclobenzaprine)

+

cocaine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + cocaine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• codeine
Tonmya (cyclobenzaprine)

+

codeine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + codeine

avoid combo if antitussive use; otherwise, use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• desipramine
Tonmya (cyclobenzaprine)

+

desipramine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + desipramine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects (additive effects)

• desvenlafaxine
Tonmya (cyclobenzaprine)

+

desvenlafaxine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + desvenlafaxine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• dexmethylphenidate
Tonmya (cyclobenzaprine)

+

dexmethylphenidate

1 interaction

Avoid/Use Alternative

cyclobenzaprine + dexmethylphenidate

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dextroamphetamine
Tonmya (cyclobenzaprine)

+

dextroamphetamine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + dextroamphetamine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. dextroamphetamine start dose: combo may incr. risk of serotonin syndrome (additive effects)

• dextromethorphan
Tonmya (cyclobenzaprine)

+

dextromethorphan

1 interaction

Avoid/Use Alternative

cyclobenzaprine + dextromethorphan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dihydrocodeine
Tonmya (cyclobenzaprine)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + dihydrocodeine

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• dihydroergotamine
Tonmya (cyclobenzaprine)

+

dihydroergotamine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + dihydroergotamine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• doxepin
Tonmya (cyclobenzaprine)

+

doxepin

1 interaction

Avoid/Use Alternative

cyclobenzaprine + doxepin

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects, incl. hyperthermia (additive effects)

• doxepin topical
Tonmya (cyclobenzaprine)

+

doxepin topical

1 interaction

Avoid/Use Alternative

cyclobenzaprine + doxepin topical

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects (additive effects)

• doxylamine
Tonmya (cyclobenzaprine)

+

doxylamine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting, otherwise caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• duloxetine
Tonmya (cyclobenzaprine)

+

duloxetine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + duloxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• eletriptan
Tonmya (cyclobenzaprine)

+

eletriptan

1 interaction

Avoid/Use Alternative

cyclobenzaprine + eletriptan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• eluxadoline
Tonmya (cyclobenzaprine)

+

eluxadoline

1 interaction

Avoid/Use Alternative

cyclobenzaprine + eluxadoline

avoid combo: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• ergotamine
Tonmya (cyclobenzaprine)

+

ergotamine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + ergotamine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• escitalopram
Tonmya (cyclobenzaprine)

+

escitalopram

1 interaction

Avoid/Use Alternative

cyclobenzaprine + escitalopram

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• ethanol
Tonmya (cyclobenzaprine)

+

ethanol

1 interaction

Avoid/Use Alternative

cyclobenzaprine + ethanol

avoid combo: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• fenfluramine
Tonmya (cyclobenzaprine)

+

fenfluramine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + fenfluramine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• fentanyl
Tonmya (cyclobenzaprine)

+

fentanyl

1 interaction

Avoid/Use Alternative

cyclobenzaprine + fentanyl

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• fluoxetine
Tonmya (cyclobenzaprine)

+

fluoxetine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + fluoxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• fluvoxamine
Tonmya (cyclobenzaprine)

+

fluvoxamine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + fluvoxamine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• frovatriptan
Tonmya (cyclobenzaprine)

+

frovatriptan

1 interaction

Avoid/Use Alternative

cyclobenzaprine + frovatriptan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• gepirone
Tonmya (cyclobenzaprine)

+

gepirone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + gepirone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• glucagon
Tonmya (cyclobenzaprine)

+

glucagon

1 interaction

Avoid/Use Alternative

cyclobenzaprine + glucagon

avoid combo if glucagon used as radiologic diagnostic aid: combo may incr. risk of severe constipation, paralytic ileus, other GI adverse effects (additive effects)

• glycopyrronium topical
Tonmya (cyclobenzaprine)

+

glycopyrronium topical

1 interaction

Avoid/Use Alternative

cyclobenzaprine + glycopyrronium topical

avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

• granisetron
Tonmya (cyclobenzaprine)

+

granisetron

1 interaction

Avoid/Use Alternative

cyclobenzaprine + granisetron

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• hydrocodone
Tonmya (cyclobenzaprine)

+

hydrocodone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + hydrocodone

avoid combo if antitussive use; otherwise, use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• hydromorphone
Tonmya (cyclobenzaprine)

+

hydromorphone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + hydromorphone

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• imipramine
Tonmya (cyclobenzaprine)

+

imipramine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + imipramine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects (additive effects)

• iohexol
Tonmya (cyclobenzaprine)

+

iohexol

1 interaction

Avoid/Use Alternative

cyclobenzaprine + iohexol

avoid combo if intrathecal iohexol use: combo may incr. risk of seizures (additive effects)

• isoniazid
Tonmya (cyclobenzaprine)

+

isoniazid

1 interaction

Avoid/Use Alternative

cyclobenzaprine + isoniazid

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, isoniazid inhibits monoamine oxidase)

• kava
Tonmya (cyclobenzaprine)

+

kava

1 interaction

Avoid/Use Alternative

cyclobenzaprine + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• kratom
Tonmya (cyclobenzaprine)

+

kratom

1 interaction

Avoid/Use Alternative

cyclobenzaprine + kratom

use alternative or monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• lasmiditan
Tonmya (cyclobenzaprine)

+

lasmiditan

1 interaction

Avoid/Use Alternative

cyclobenzaprine + lasmiditan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• levomilnacipran
Tonmya (cyclobenzaprine)

+

levomilnacipran

1 interaction

Avoid/Use Alternative

cyclobenzaprine + levomilnacipran

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• levorphanol
Tonmya (cyclobenzaprine)

+

levorphanol

1 interaction

Avoid/Use Alternative

cyclobenzaprine + levorphanol

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• linezolid
Tonmya (cyclobenzaprine)

+

linezolid

1 interaction

Avoid/Use Alternative

cyclobenzaprine + linezolid

use alternative or hold cyclobenzaprine if urgent use; monitor serotonin syndrome sx x2wk after cyclobenzaprine D/C or 24h after last linezolid dose: combo may incr. risk of serotonin syndrome (additive effects, linezolid reversibly inhibits monoamine oxidase)

• lisdexamfetamine
Tonmya (cyclobenzaprine)

+

lisdexamfetamine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + lisdexamfetamine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. lisdexamfetamine start dose: combo may incr. risk of serotonin syndrome (additive effects)

• lithium
Tonmya (cyclobenzaprine)

+

lithium

1 interaction

Avoid/Use Alternative

cyclobenzaprine + lithium

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• meperidine
Tonmya (cyclobenzaprine)

+

meperidine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + meperidine

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• metaxalone
Tonmya (cyclobenzaprine)

+

metaxalone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + metaxalone

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS and resp. depression, psychomotor impairment, serotonin syndrome (additive effects)

• methadone
Tonmya (cyclobenzaprine)

+

methadone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + methadone

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• methamphetamine
Tonmya (cyclobenzaprine)

+

methamphetamine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + methamphetamine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. methamphetamine start dose: combo may incr. risk of serotonin syndrome (additive effects)

• methylene blue oral
Tonmya (cyclobenzaprine)

+

methylene blue oral

1 interaction

Avoid/Use Alternative

cyclobenzaprine + methylene blue oral

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• methylergonovine
Tonmya (cyclobenzaprine)

+

methylergonovine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + methylergonovine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• methylphenidate
Tonmya (cyclobenzaprine)

+

methylphenidate

1 interaction

Avoid/Use Alternative

cyclobenzaprine + methylphenidate

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• metoclopramide
Tonmya (cyclobenzaprine)

+

metoclopramide

1 interaction

Avoid/Use Alternative

cyclobenzaprine + metoclopramide

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may decr. metoclopramide efficacy (additive effects; antagonistic effects; absorption of oral metoclopramide affected by delayed gastric emptying)

• midazolam
Tonmya (cyclobenzaprine)

+

midazolam

1 interaction

Avoid/Use Alternative

cyclobenzaprine + midazolam

use alternative or monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• milnacipran
Tonmya (cyclobenzaprine)

+

milnacipran

1 interaction

Avoid/Use Alternative

cyclobenzaprine + milnacipran

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• mirtazapine
Tonmya (cyclobenzaprine)

+

mirtazapine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + mirtazapine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects (additive effects)

• morphine
Tonmya (cyclobenzaprine)

+

morphine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + morphine

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• nalbuphine
Tonmya (cyclobenzaprine)

+

nalbuphine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + nalbuphine

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• naratriptan
Tonmya (cyclobenzaprine)

+

naratriptan

1 interaction

Avoid/Use Alternative

cyclobenzaprine + naratriptan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• nefazodone
Tonmya (cyclobenzaprine)

+

nefazodone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + nefazodone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• nortriptyline
Tonmya (cyclobenzaprine)

+

nortriptyline

1 interaction

Avoid/Use Alternative

cyclobenzaprine + nortriptyline

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects (additive effects)

• oliceridine
Tonmya (cyclobenzaprine)

+

oliceridine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + oliceridine

use alternative or monitor BP, resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• ondansetron
Tonmya (cyclobenzaprine)

+

ondansetron

1 interaction

Avoid/Use Alternative

cyclobenzaprine + ondansetron

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• opium
Tonmya (cyclobenzaprine)

+

opium

1 interaction

Avoid/Use Alternative

cyclobenzaprine + opium

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• oxybate
Tonmya (cyclobenzaprine)

+

oxybate

1 interaction

Avoid/Use Alternative

cyclobenzaprine + oxybate

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects)

• oxycodone
Tonmya (cyclobenzaprine)

+

oxycodone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + oxycodone

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. oxycodone start dose by at least 50%, consider decr. cyclobenzaprine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• oxymorphone
Tonmya (cyclobenzaprine)

+

oxymorphone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + oxymorphone

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. oxymorphone start dose by at least 50%, consider decr. cyclobenzaprine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• palonosetron
Tonmya (cyclobenzaprine)

+

palonosetron

1 interaction

Avoid/Use Alternative

cyclobenzaprine + palonosetron

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• paroxetine
Tonmya (cyclobenzaprine)

+

paroxetine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + paroxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• pentazocine
Tonmya (cyclobenzaprine)

+

pentazocine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + pentazocine

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• pramlintide
Tonmya (cyclobenzaprine)

+

pramlintide

1 interaction

Avoid/Use Alternative

cyclobenzaprine + pramlintide

consider alternative: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• procarbazine
Tonmya (cyclobenzaprine)

+

procarbazine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + procarbazine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects, procarbazine inhibits monoamine oxidase)

• promethazine
Tonmya (cyclobenzaprine)

+

promethazine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + promethazine

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment, seizures, anticholinergic adverse effects (additive effects)

• protriptyline
Tonmya (cyclobenzaprine)

+

protriptyline

1 interaction

Avoid/Use Alternative

cyclobenzaprine + protriptyline

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects, incl. hyperthermia (additive effects)

• remifentanil
Tonmya (cyclobenzaprine)

+

remifentanil

1 interaction

Avoid/Use Alternative

cyclobenzaprine + remifentanil

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• revefenacin inhaled
Tonmya (cyclobenzaprine)

+

revefenacin inhaled

1 interaction

Avoid/Use Alternative

cyclobenzaprine + revefenacin inhaled

avoid combo: combo may incr. anticholinergic adverse effects (additive effects)

• rivastigmine
Tonmya (cyclobenzaprine)

+

rivastigmine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + rivastigmine

use alternative: combo may decr. efficacy of both drugs (antagonistic effects)

• rizatriptan
Tonmya (cyclobenzaprine)

+

rizatriptan

1 interaction

Avoid/Use Alternative

cyclobenzaprine + rizatriptan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• ropeginterferon alfa-2b
Tonmya (cyclobenzaprine)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

cyclobenzaprine + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• SAMe
Tonmya (cyclobenzaprine)

+

SAMe

1 interaction

Avoid/Use Alternative

cyclobenzaprine + SAMe

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• sertraline
Tonmya (cyclobenzaprine)

+

sertraline

1 interaction

Avoid/Use Alternative

cyclobenzaprine + sertraline

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• sofpironium topical
Tonmya (cyclobenzaprine)

+

sofpironium topical

1 interaction

Avoid/Use Alternative

cyclobenzaprine + sofpironium topical

avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

• St. John's wort
Tonmya (cyclobenzaprine)

+

St. John's wort

1 interaction

Avoid/Use Alternative

cyclobenzaprine + St. John's wort

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• sufentanil
Tonmya (cyclobenzaprine)

+

sufentanil

1 interaction

Avoid/Use Alternative

cyclobenzaprine + sufentanil

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. sufentanil start dose, consider decr. cyclobenzaprine dose, use lowest effective doses: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• sumatriptan
Tonmya (cyclobenzaprine)

+

sumatriptan

1 interaction

Avoid/Use Alternative

cyclobenzaprine + sumatriptan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• tapentadol
Tonmya (cyclobenzaprine)

+

tapentadol

1 interaction

Avoid/Use Alternative

cyclobenzaprine + tapentadol

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, severe constipation, paralytic ileus, urinary retention (additive effects)

• thalidomide
Tonmya (cyclobenzaprine)

+

thalidomide

1 interaction

Avoid/Use Alternative

cyclobenzaprine + thalidomide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tramadol
Tonmya (cyclobenzaprine)

+

tramadol

1 interaction

Avoid/Use Alternative

cyclobenzaprine + tramadol

use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome, seizures, severe constipation, paralytic ileus, urinary retention (additive effects)

• trazodone
Tonmya (cyclobenzaprine)

+

trazodone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + trazodone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• trimethobenzamide
Tonmya (cyclobenzaprine)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

cyclobenzaprine + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimipramine
Tonmya (cyclobenzaprine)

+

trimipramine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + trimipramine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, anticholinergic adverse effects (additive effects)

• venlafaxine
Tonmya (cyclobenzaprine)

+

venlafaxine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + venlafaxine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• vilazodone
Tonmya (cyclobenzaprine)

+

vilazodone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + vilazodone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• vortioxetine
Tonmya (cyclobenzaprine)

+

vortioxetine

1 interaction

Avoid/Use Alternative

cyclobenzaprine + vortioxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• yohimbe
Tonmya (cyclobenzaprine)

+

yohimbe

1 interaction

Avoid/Use Alternative

cyclobenzaprine + yohimbe

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, yohimbe inhibits monoamine oxidase)

• ziprasidone
Tonmya (cyclobenzaprine)

+

ziprasidone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + ziprasidone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyperthermia (additive effects)

• zolmitriptan
Tonmya (cyclobenzaprine)

+

zolmitriptan

1 interaction

Avoid/Use Alternative

cyclobenzaprine + zolmitriptan

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment (additive effects)

• zuranolone
Tonmya (cyclobenzaprine)

+

zuranolone

1 interaction

Avoid/Use Alternative

cyclobenzaprine + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• alprazolam
Tonmya (cyclobenzaprine)

+

alprazolam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + alprazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• bupropion
Tonmya (cyclobenzaprine)

+

bupropion

1 interaction

Monitor/Modify Tx

cyclobenzaprine + bupropion

monitor serotonin syndrome sx, especially during initiation/titration; consider lower bupropion doses: combo may incr. risk of seizures, serotonin syndrome (additive effects)

• chlorpromazine
Tonmya (cyclobenzaprine)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + chlorpromazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• clobazam
Tonmya (cyclobenzaprine)

+

clobazam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + clobazam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• clonazepam
Tonmya (cyclobenzaprine)

+

clonazepam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + clonazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• clorazepate
Tonmya (cyclobenzaprine)

+

clorazepate

1 interaction

Monitor/Modify Tx

cyclobenzaprine + clorazepate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• daridorexant
Tonmya (cyclobenzaprine)

+

daridorexant

1 interaction

Monitor/Modify Tx

cyclobenzaprine + daridorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• desflurane
Tonmya (cyclobenzaprine)

+

desflurane

1 interaction

Monitor/Modify Tx

cyclobenzaprine + desflurane

consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• dexmedetomidine
Tonmya (cyclobenzaprine)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + dexmedetomidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine injection
Tonmya (cyclobenzaprine)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

cyclobenzaprine + dexmedetomidine injection

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• diazepam
Tonmya (cyclobenzaprine)

+

diazepam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + diazepam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• droperidol
Tonmya (cyclobenzaprine)

+

droperidol

1 interaction

Monitor/Modify Tx

cyclobenzaprine + droperidol

decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ephedra
Tonmya (cyclobenzaprine)

+

ephedra

1 interaction

Monitor/Modify Tx

cyclobenzaprine + ephedra

monitor BP: combo may decr. vasopressor, cardiostimulating effects (antagonistic effects)

• esketamine
Tonmya (cyclobenzaprine)

+

esketamine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + esketamine

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• eszopiclone
Tonmya (cyclobenzaprine)

+

eszopiclone

1 interaction

Monitor/Modify Tx

cyclobenzaprine + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• etomidate
Tonmya (cyclobenzaprine)

+

etomidate

1 interaction

Monitor/Modify Tx

cyclobenzaprine + etomidate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• fluphenazine
Tonmya (cyclobenzaprine)

+

fluphenazine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + fluphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• flurazepam
Tonmya (cyclobenzaprine)

+

flurazepam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + flurazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• gabapentin
Tonmya (cyclobenzaprine)

+

gabapentin

1 interaction

Monitor/Modify Tx

cyclobenzaprine + gabapentin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• gabapentin enacarbil
Tonmya (cyclobenzaprine)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

cyclobenzaprine + gabapentin enacarbil

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• hydroxyzine
Tonmya (cyclobenzaprine)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + hydroxyzine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• ifosfamide
Tonmya (cyclobenzaprine)

+

ifosfamide

1 interaction

Monitor/Modify Tx

cyclobenzaprine + ifosfamide

D/C one or both drugs if encephalopathy occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• iopamidol
Tonmya (cyclobenzaprine)

+

iopamidol

1 interaction

Monitor/Modify Tx

cyclobenzaprine + iopamidol

caution advised if intrathecal iopamidol use; consider holding cyclobenzaprine at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• ketamine
Tonmya (cyclobenzaprine)

+

ketamine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + ketamine

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression (incl. life-threatening), psychomotor impairment (additive effects)

• lemborexant
Tonmya (cyclobenzaprine)

+

lemborexant

1 interaction

Monitor/Modify Tx

cyclobenzaprine + lemborexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lorazepam
Tonmya (cyclobenzaprine)

+

lorazepam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + lorazepam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• methylene blue injection
Tonmya (cyclobenzaprine)

+

methylene blue injection

1 interaction

Monitor/Modify Tx

cyclobenzaprine + methylene blue injection

hold cyclobenzaprine if emergency use; monitor serotonin syndrome sx up to 4h after last methylene blue dose; may resume cyclobenzaprine 72h after last methylene blue dose: combo may incr. risk of serotonin syndrome (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• nelarabine
Tonmya (cyclobenzaprine)

+

nelarabine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• olanzapine
Tonmya (cyclobenzaprine)

+

olanzapine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + olanzapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (incl. orthostasis), life-threatening anticholinergic adverse effects, incl. constipation, paralytic ileus, hyperthermia (additive effects)

• opicapone
Tonmya (cyclobenzaprine)

+

opicapone

1 interaction

Monitor/Modify Tx

cyclobenzaprine + opicapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• oxazepam
Tonmya (cyclobenzaprine)

+

oxazepam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + oxazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• oxybutynin
Tonmya (cyclobenzaprine)

+

oxybutynin

1 interaction

Monitor/Modify Tx

cyclobenzaprine + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects; somnolence less likely w/ oxybutynin transdermal patch (additive effects)

• pentobarbital
Tonmya (cyclobenzaprine)

+

pentobarbital

1 interaction

Monitor/Modify Tx

cyclobenzaprine + pentobarbital

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• perphenazine
Tonmya (cyclobenzaprine)

+

perphenazine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + perphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• phenobarbital
Tonmya (cyclobenzaprine)

+

phenobarbital

1 interaction

Monitor/Modify Tx

cyclobenzaprine + phenobarbital

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• pregabalin
Tonmya (cyclobenzaprine)

+

pregabalin

1 interaction

Monitor/Modify Tx

cyclobenzaprine + pregabalin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• primidone
Tonmya (cyclobenzaprine)

+

primidone

1 interaction

Monitor/Modify Tx

cyclobenzaprine + primidone

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• propofol
Tonmya (cyclobenzaprine)

+

propofol

1 interaction

Monitor/Modify Tx

cyclobenzaprine + propofol

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quazepam
Tonmya (cyclobenzaprine)

+

quazepam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + quazepam

consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• remimazolam
Tonmya (cyclobenzaprine)

+

remimazolam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + remimazolam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• sevoflurane
Tonmya (cyclobenzaprine)

+

sevoflurane

1 interaction

Monitor/Modify Tx

cyclobenzaprine + sevoflurane

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• suvorexant
Tonmya (cyclobenzaprine)

+

suvorexant

1 interaction

Monitor/Modify Tx

cyclobenzaprine + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thioridazine
Tonmya (cyclobenzaprine)

+

thioridazine

1 interaction

Monitor/Modify Tx

cyclobenzaprine + thioridazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• thiothixene
Tonmya (cyclobenzaprine)

+

thiothixene

1 interaction

Monitor/Modify Tx

cyclobenzaprine + thiothixene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• triazolam
Tonmya (cyclobenzaprine)

+

triazolam

1 interaction

Monitor/Modify Tx

cyclobenzaprine + triazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• zaleplon
Tonmya (cyclobenzaprine)

+

zaleplon

1 interaction

Monitor/Modify Tx

cyclobenzaprine + zaleplon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziconotide
Tonmya (cyclobenzaprine)

+

ziconotide

1 interaction

Monitor/Modify Tx

cyclobenzaprine + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Tonmya (cyclobenzaprine)

+

zolpidem

1 interaction

Monitor/Modify Tx

cyclobenzaprine + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Caution Advised

• aceclidine ophthalmic
Tonmya (cyclobenzaprine)

+

aceclidine ophthalmic

1 interaction

Caution Advised

cyclobenzaprine + aceclidine ophthalmic

caution advised: combo may decr. aceclidine efficacy (antagonistic effects)

• acetazolamide
Tonmya (cyclobenzaprine)

+

acetazolamide

1 interaction

Caution Advised

cyclobenzaprine + acetazolamide

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• allopurinol
Tonmya (cyclobenzaprine)

+

allopurinol

1 interaction

Caution Advised

cyclobenzaprine + allopurinol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• alosetron
Tonmya (cyclobenzaprine)

+

alosetron

1 interaction

Caution Advised

cyclobenzaprine + alosetron

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• amantadine
Tonmya (cyclobenzaprine)

+

amantadine

1 interaction

Caution Advised

cyclobenzaprine + amantadine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• apomorphine
Tonmya (cyclobenzaprine)

+

apomorphine

1 interaction

Caution Advised

cyclobenzaprine + apomorphine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• apraclonidine ophthalmic
Tonmya (cyclobenzaprine)

+

apraclonidine ophthalmic

1 interaction

Caution Advised

cyclobenzaprine + apraclonidine ophthalmic

caution advised if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole bimonthly injection
Tonmya (cyclobenzaprine)

+

aripiprazole bimonthly injection

1 interaction

Caution Advised

cyclobenzaprine + aripiprazole bimonthly injection

caution advised: combo may incr. risk of hyperthermia, CNS depression, psychomotor impairment (additive effects)

• aripiprazole lauroxil
Tonmya (cyclobenzaprine)

+

aripiprazole lauroxil

1 interaction

Caution Advised

cyclobenzaprine + aripiprazole lauroxil

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• aripiprazole monthly injection
Tonmya (cyclobenzaprine)

+

aripiprazole monthly injection

1 interaction

Caution Advised

cyclobenzaprine + aripiprazole monthly injection

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• aripiprazole oral
Tonmya (cyclobenzaprine)

+

aripiprazole oral

1 interaction

Caution Advised

cyclobenzaprine + aripiprazole oral

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• asenapine
Tonmya (cyclobenzaprine)

+

asenapine

1 interaction

Caution Advised

cyclobenzaprine + asenapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• atropine
Tonmya (cyclobenzaprine)

+

atropine

1 interaction

Caution Advised

cyclobenzaprine + atropine

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• atropine ophthalmic
Tonmya (cyclobenzaprine)

+

atropine ophthalmic

1 interaction

Caution Advised

cyclobenzaprine + atropine ophthalmic

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• baclofen
Tonmya (cyclobenzaprine)

+

baclofen

1 interaction

Caution Advised

cyclobenzaprine + baclofen

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• baclofen intrathecal
Tonmya (cyclobenzaprine)

+

baclofen intrathecal

1 interaction

Caution Advised

cyclobenzaprine + baclofen intrathecal

caution advised: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• barium
Tonmya (cyclobenzaprine)

+

barium

1 interaction

Caution Advised

cyclobenzaprine + barium

caution advised: combo may incr. risk of intestinal obstruction (additive effects)

• belladonna alkaloids
Tonmya (cyclobenzaprine)

+

belladonna alkaloids

1 interaction

Caution Advised

cyclobenzaprine + belladonna alkaloids

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• bethanechol
Tonmya (cyclobenzaprine)

+

bethanechol

1 interaction

Caution Advised

cyclobenzaprine + bethanechol

caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

• botulinum toxin
Tonmya (cyclobenzaprine)

+

botulinum toxin

1 interaction

Caution Advised

cyclobenzaprine + botulinum toxin

caution advised: combo may incr. risk of anticholinergic adverse effects, excessive muscle weakness (additive effects)

• brexpiprazole
Tonmya (cyclobenzaprine)

+

brexpiprazole

1 interaction

Caution Advised

cyclobenzaprine + brexpiprazole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• brimonidine ophthalmic
Tonmya (cyclobenzaprine)

+

brimonidine ophthalmic

1 interaction

Caution Advised

cyclobenzaprine + brimonidine ophthalmic

caution advised if elevated IOP use; OTC ocular redness use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brimonidine topical
Tonmya (cyclobenzaprine)

+

brimonidine topical

1 interaction

Caution Advised

cyclobenzaprine + brimonidine topical

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brivaracetam
Tonmya (cyclobenzaprine)

+

brivaracetam

1 interaction

Caution Advised

cyclobenzaprine + brivaracetam

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• brompheniramine
Tonmya (cyclobenzaprine)

+

brompheniramine

1 interaction

Caution Advised

cyclobenzaprine + brompheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• busulfan
Tonmya (cyclobenzaprine)

+

busulfan

1 interaction

Caution Advised

cyclobenzaprine + busulfan

caution advised: combo may incr. risk of seizures (additive effects)

• cannabidiol
Tonmya (cyclobenzaprine)

+

cannabidiol

1 interaction

Caution Advised

cyclobenzaprine + cannabidiol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• cannabis
Tonmya (cyclobenzaprine)

+

cannabis

1 interaction

Caution Advised

cyclobenzaprine + cannabis

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• carbinoxamine
Tonmya (cyclobenzaprine)

+

carbinoxamine

1 interaction

Caution Advised

cyclobenzaprine + carbinoxamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• cariprazine
Tonmya (cyclobenzaprine)

+

cariprazine

1 interaction

Caution Advised

cyclobenzaprine + cariprazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• carisoprodol
Tonmya (cyclobenzaprine)

+

carisoprodol

1 interaction

Caution Advised

cyclobenzaprine + carisoprodol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cenobamate
Tonmya (cyclobenzaprine)

+

cenobamate

1 interaction

Caution Advised

cyclobenzaprine + cenobamate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• cetirizine
Tonmya (cyclobenzaprine)

+

cetirizine

1 interaction

Caution Advised

cyclobenzaprine + cetirizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cevimeline
Tonmya (cyclobenzaprine)

+

cevimeline

1 interaction

Caution Advised

cyclobenzaprine + cevimeline

caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

• chamomile, German
Tonmya (cyclobenzaprine)

+

chamomile, German

1 interaction

Caution Advised

cyclobenzaprine + chamomile, German

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlophedianol
Tonmya (cyclobenzaprine)

+

chlophedianol

1 interaction

Caution Advised

cyclobenzaprine + chlophedianol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• chlorambucil
Tonmya (cyclobenzaprine)

+

chlorambucil

1 interaction

Caution Advised

cyclobenzaprine + chlorambucil

caution advised: combo may incr. risk of seizures (additive effects)

• chlordiazepoxide
Tonmya (cyclobenzaprine)

+

chlordiazepoxide

1 interaction

Caution Advised

cyclobenzaprine + chlordiazepoxide

caution advised: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• chlorpheniramine
Tonmya (cyclobenzaprine)

+

chlorpheniramine

1 interaction

Caution Advised

cyclobenzaprine + chlorpheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• chlorzoxazone
Tonmya (cyclobenzaprine)

+

chlorzoxazone

1 interaction

Caution Advised

cyclobenzaprine + chlorzoxazone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cisapride
Tonmya (cyclobenzaprine)

+

cisapride

1 interaction

Caution Advised

cyclobenzaprine + cisapride

caution advised: combo may decr. cisapride efficacy (antagonistic effects)

• clemastine
Tonmya (cyclobenzaprine)

+

clemastine

1 interaction

Caution Advised

cyclobenzaprine + clemastine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• clidinium
Tonmya (cyclobenzaprine)

+

clidinium

1 interaction

Caution Advised

cyclobenzaprine + clidinium

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• cyclopentolate ophthalmic
Tonmya (cyclobenzaprine)

+

cyclopentolate ophthalmic

1 interaction

Caution Advised

cyclobenzaprine + cyclopentolate ophthalmic

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• cyproheptadine
Tonmya (cyclobenzaprine)

+

cyproheptadine

1 interaction

Caution Advised

cyclobenzaprine + cyproheptadine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• dantrolene
Tonmya (cyclobenzaprine)

+

dantrolene

1 interaction

Caution Advised

cyclobenzaprine + dantrolene

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darifenacin
Tonmya (cyclobenzaprine)

+

darifenacin

1 interaction

Caution Advised

cyclobenzaprine + darifenacin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• deutetrabenazine
Tonmya (cyclobenzaprine)

+

deutetrabenazine

1 interaction

Caution Advised

cyclobenzaprine + deutetrabenazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexbrompheniramine
Tonmya (cyclobenzaprine)

+

dexbrompheniramine

1 interaction

Caution Advised

cyclobenzaprine + dexbrompheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• dexchlorpheniramine
Tonmya (cyclobenzaprine)

+

dexchlorpheniramine

1 interaction

Caution Advised

cyclobenzaprine + dexchlorpheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• dichlorphenamide
Tonmya (cyclobenzaprine)

+

dichlorphenamide

1 interaction

Caution Advised

cyclobenzaprine + dichlorphenamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dicyclomine
Tonmya (cyclobenzaprine)

+

dicyclomine

1 interaction

Caution Advised

cyclobenzaprine + dicyclomine

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• difelikefalin
Tonmya (cyclobenzaprine)

+

difelikefalin

1 interaction

Caution Advised

cyclobenzaprine + difelikefalin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difenoxin
Tonmya (cyclobenzaprine)

+

difenoxin

1 interaction

Caution Advised

cyclobenzaprine + difenoxin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, severe constipation, paralytic ileus (additive effects)

• dimenhydrinate
Tonmya (cyclobenzaprine)

+

dimenhydrinate

1 interaction

Caution Advised

cyclobenzaprine + dimenhydrinate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• diphenhydramine
Tonmya (cyclobenzaprine)

+

diphenhydramine

1 interaction

Caution Advised

cyclobenzaprine + diphenhydramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• diphenoxylate
Tonmya (cyclobenzaprine)

+

diphenoxylate

1 interaction

Caution Advised

cyclobenzaprine + diphenoxylate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, severe constipation, paralytic ileus (additive effects)

• disopyramide
Tonmya (cyclobenzaprine)

+

disopyramide

1 interaction

Caution Advised

cyclobenzaprine + disopyramide

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• domperidone
Tonmya (cyclobenzaprine)

+

domperidone

1 interaction

Caution Advised

cyclobenzaprine + domperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may decr. domperidone efficacy (additive effects; antagonistic effects)

• donepezil
Tonmya (cyclobenzaprine)

+

donepezil

1 interaction

Caution Advised

cyclobenzaprine + donepezil

caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

• doxazosin
Tonmya (cyclobenzaprine)

+

doxazosin

1 interaction

Caution Advised

cyclobenzaprine + doxazosin

caution advised w/ doxazosin ER dosage form: combo may incr. doxazosin levels, risk of adverse effects (absorption increased)

• dronabinol
Tonmya (cyclobenzaprine)

+

dronabinol

1 interaction

Caution Advised

cyclobenzaprine + dronabinol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• efavirenz
Tonmya (cyclobenzaprine)

+

efavirenz

1 interaction

Caution Advised

cyclobenzaprine + efavirenz

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• entacapone
Tonmya (cyclobenzaprine)

+

entacapone

1 interaction

Caution Advised

cyclobenzaprine + entacapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• entrectinib
Tonmya (cyclobenzaprine)

+

entrectinib

1 interaction

Caution Advised

cyclobenzaprine + entrectinib

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• erenumab
Tonmya (cyclobenzaprine)

+

erenumab

1 interaction

Caution Advised

cyclobenzaprine + erenumab

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• erythromycin
Tonmya (cyclobenzaprine)

+

erythromycin

1 interaction

Caution Advised

cyclobenzaprine + erythromycin

caution advised: combo may decr. erythromycin efficacy when used for GI promotility (antagonistic effects)

• eslicarbazepine acetate
Tonmya (cyclobenzaprine)

+

eslicarbazepine acetate

1 interaction

Caution Advised

cyclobenzaprine + eslicarbazepine acetate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• estazolam
Tonmya (cyclobenzaprine)

+

estazolam

1 interaction

Caution Advised

cyclobenzaprine + estazolam

caution advised: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• ethanol (in some formulations)
Tonmya (cyclobenzaprine)

+

ethanol (in some formulations)

1 interaction

Caution Advised

cyclobenzaprine + ethanol (in some formulations)

caution advised: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• ethosuximide
Tonmya (cyclobenzaprine)

+

ethosuximide

1 interaction

Caution Advised

cyclobenzaprine + ethosuximide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• felbamate
Tonmya (cyclobenzaprine)

+

felbamate

1 interaction

Caution Advised

cyclobenzaprine + felbamate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• fesoterodine
Tonmya (cyclobenzaprine)

+

fesoterodine

1 interaction

Caution Advised

cyclobenzaprine + fesoterodine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• flavoxate
Tonmya (cyclobenzaprine)

+

flavoxate

1 interaction

Caution Advised

cyclobenzaprine + flavoxate

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• flibanserin
Tonmya (cyclobenzaprine)

+

flibanserin

1 interaction

Caution Advised

cyclobenzaprine + flibanserin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• foslevodopa
Tonmya (cyclobenzaprine)

+

foslevodopa

1 interaction

Caution Advised

cyclobenzaprine + foslevodopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fosphenytoin
Tonmya (cyclobenzaprine)

+

fosphenytoin

1 interaction

Caution Advised

cyclobenzaprine + fosphenytoin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• galantamine
Tonmya (cyclobenzaprine)

+

galantamine

1 interaction

Caution Advised

cyclobenzaprine + galantamine

caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

• ganaxolone
Tonmya (cyclobenzaprine)

+

ganaxolone

1 interaction

Caution Advised

cyclobenzaprine + ganaxolone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• glofitamab
Tonmya (cyclobenzaprine)

+

glofitamab

1 interaction

Caution Advised

cyclobenzaprine + glofitamab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• glycopyrrolate
Tonmya (cyclobenzaprine)

+

glycopyrrolate

1 interaction

Caution Advised

cyclobenzaprine + glycopyrrolate

caution advised: combo may incr. CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• glycopyrrolate inhaled
Tonmya (cyclobenzaprine)

+

glycopyrrolate inhaled

1 interaction

Caution Advised

cyclobenzaprine + glycopyrrolate inhaled

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• guanfacine
Tonmya (cyclobenzaprine)

+

guanfacine

1 interaction

Caution Advised

cyclobenzaprine + guanfacine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• haloperidol
Tonmya (cyclobenzaprine)

+

haloperidol

1 interaction

Caution Advised

cyclobenzaprine + haloperidol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• homatropine
Tonmya (cyclobenzaprine)

+

homatropine

1 interaction

Caution Advised

cyclobenzaprine + homatropine

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• hydrochlorothiazide
Tonmya (cyclobenzaprine)

+

hydrochlorothiazide

1 interaction

Caution Advised

cyclobenzaprine + hydrochlorothiazide

caution advised: combo may incr. hydrochlorothiazide levels, risk of adverse effects (absorption increased)

• hydroxychloroquine
Tonmya (cyclobenzaprine)

+

hydroxychloroquine

1 interaction

Caution Advised

cyclobenzaprine + hydroxychloroquine

caution advised: combo may incr. risk of seizures (additive effects)

• hyoscyamine
Tonmya (cyclobenzaprine)

+

hyoscyamine

1 interaction

Caution Advised

cyclobenzaprine + hyoscyamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• iloperidone
Tonmya (cyclobenzaprine)

+

iloperidone

1 interaction

Caution Advised

cyclobenzaprine + iloperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• ipratropium inhaled
Tonmya (cyclobenzaprine)

+

ipratropium inhaled

1 interaction

Caution Advised

cyclobenzaprine + ipratropium inhaled

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• ipratropium nasal
Tonmya (cyclobenzaprine)

+

ipratropium nasal

1 interaction

Caution Advised

cyclobenzaprine + ipratropium nasal

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• isoflurane
Tonmya (cyclobenzaprine)

+

isoflurane

1 interaction

Caution Advised

cyclobenzaprine + isoflurane

caution advised: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• lacosamide
Tonmya (cyclobenzaprine)

+

lacosamide

1 interaction

Caution Advised

cyclobenzaprine + lacosamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• lamotrigine
Tonmya (cyclobenzaprine)

+

lamotrigine

1 interaction

Caution Advised

cyclobenzaprine + lamotrigine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• levetiracetam
Tonmya (cyclobenzaprine)

+

levetiracetam

1 interaction

Caution Advised

cyclobenzaprine + levetiracetam

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• levocetirizine
Tonmya (cyclobenzaprine)

+

levocetirizine

1 interaction

Caution Advised

cyclobenzaprine + levocetirizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levodopa
Tonmya (cyclobenzaprine)

+

levodopa

1 interaction

Caution Advised

cyclobenzaprine + levodopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• linvoseltamab
Tonmya (cyclobenzaprine)

+

linvoseltamab

1 interaction

Caution Advised

cyclobenzaprine + linvoseltamab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lofexidine
Tonmya (cyclobenzaprine)

+

lofexidine

1 interaction

Caution Advised

cyclobenzaprine + lofexidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• loperamide
Tonmya (cyclobenzaprine)

+

loperamide

1 interaction

Caution Advised

cyclobenzaprine + loperamide

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• loxapine
Tonmya (cyclobenzaprine)

+

loxapine

1 interaction

Caution Advised

cyclobenzaprine + loxapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• lumateperone
Tonmya (cyclobenzaprine)

+

lumateperone

1 interaction

Caution Advised

cyclobenzaprine + lumateperone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• lurasidone
Tonmya (cyclobenzaprine)

+

lurasidone

1 interaction

Caution Advised

cyclobenzaprine + lurasidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• magnesium citrate
Tonmya (cyclobenzaprine)

+

magnesium citrate

1 interaction

Caution Advised

cyclobenzaprine + magnesium citrate

caution advised, especially if magnesium citrate bowel prep use: combo may incr. risk of seizures (additive effects)

• meclizine
Tonmya (cyclobenzaprine)

+

meclizine

1 interaction

Caution Advised

cyclobenzaprine + meclizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• melatonin
Tonmya (cyclobenzaprine)

+

melatonin

1 interaction

Caution Advised

cyclobenzaprine + melatonin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• meprobamate
Tonmya (cyclobenzaprine)

+

meprobamate

1 interaction

Caution Advised

cyclobenzaprine + meprobamate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methacholine inhaled
Tonmya (cyclobenzaprine)

+

methacholine inhaled

1 interaction

Caution Advised

cyclobenzaprine + methacholine inhaled

caution advised: combo may interfere w/ test results (antagonistic effects)

• methocarbamol
Tonmya (cyclobenzaprine)

+

methocarbamol

1 interaction

Caution Advised

cyclobenzaprine + methocarbamol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methohexital
Tonmya (cyclobenzaprine)

+

methohexital

1 interaction

Caution Advised

cyclobenzaprine + methohexital

caution advised: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• methscopolamine
Tonmya (cyclobenzaprine)

+

methscopolamine

1 interaction

Caution Advised

cyclobenzaprine + methscopolamine

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• methsuximide
Tonmya (cyclobenzaprine)

+

methsuximide

1 interaction

Caution Advised

cyclobenzaprine + methsuximide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• methyldopa
Tonmya (cyclobenzaprine)

+

methyldopa

1 interaction

Caution Advised

cyclobenzaprine + methyldopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrapone
Tonmya (cyclobenzaprine)

+

metyrapone

1 interaction

Caution Advised

cyclobenzaprine + metyrapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrosine
Tonmya (cyclobenzaprine)

+

metyrosine

1 interaction

Caution Advised

cyclobenzaprine + metyrosine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mexiletine
Tonmya (cyclobenzaprine)

+

mexiletine

1 interaction

Caution Advised

cyclobenzaprine + mexiletine

caution advised: combo may delay antiarrhythmic onset, decr. peak mexiletine levels, efficacy (absorption delayed)

• mirabegron
Tonmya (cyclobenzaprine)

+

mirabegron

1 interaction

Caution Advised

cyclobenzaprine + mirabegron

caution advised: combo may incr. risk of urinary retention (additive effects)

• mitotane
Tonmya (cyclobenzaprine)

+

mitotane

1 interaction

Caution Advised

cyclobenzaprine + mitotane

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• molindone
Tonmya (cyclobenzaprine)

+

molindone

1 interaction

Caution Advised

cyclobenzaprine + molindone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• mosunetuzumab
Tonmya (cyclobenzaprine)

+

mosunetuzumab

1 interaction

Caution Advised

cyclobenzaprine + mosunetuzumab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mycophenolate mofetil
Tonmya (cyclobenzaprine)

+

mycophenolate mofetil

1 interaction

Caution Advised

cyclobenzaprine + mycophenolate mofetil

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• naltrexone
Tonmya (cyclobenzaprine)

+

naltrexone

1 interaction

Caution Advised

cyclobenzaprine + naltrexone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• neostigmine
Tonmya (cyclobenzaprine)

+

neostigmine

1 interaction

Caution Advised

cyclobenzaprine + neostigmine

caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

• orphenadrine
Tonmya (cyclobenzaprine)

+

orphenadrine

1 interaction

Caution Advised

cyclobenzaprine + orphenadrine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• oxcarbazepine
Tonmya (cyclobenzaprine)

+

oxcarbazepine

1 interaction

Caution Advised

cyclobenzaprine + oxcarbazepine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• paliperidone
Tonmya (cyclobenzaprine)

+

paliperidone

1 interaction

Caution Advised

cyclobenzaprine + paliperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• passion flower
Tonmya (cyclobenzaprine)

+

passion flower

1 interaction

Caution Advised

cyclobenzaprine + passion flower

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• perampanel
Tonmya (cyclobenzaprine)

+

perampanel

1 interaction

Caution Advised

cyclobenzaprine + perampanel

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• pheniramine
Tonmya (cyclobenzaprine)

+

pheniramine

1 interaction

Caution Advised

cyclobenzaprine + pheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• phenytoin
Tonmya (cyclobenzaprine)

+

phenytoin

1 interaction

Caution Advised

cyclobenzaprine + phenytoin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• pilocarpine
Tonmya (cyclobenzaprine)

+

pilocarpine

1 interaction

Caution Advised

cyclobenzaprine + pilocarpine

caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

• pilocarpine ophthalmic
Tonmya (cyclobenzaprine)

+

pilocarpine ophthalmic

1 interaction

Caution Advised

cyclobenzaprine + pilocarpine ophthalmic

caution advised: combo may decr. pilocarpine efficacy (antagonistic effects)

• pimozide
Tonmya (cyclobenzaprine)

+

pimozide

1 interaction

Caution Advised

cyclobenzaprine + pimozide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• polyethylene glycol
Tonmya (cyclobenzaprine)

+

polyethylene glycol

1 interaction

Caution Advised

cyclobenzaprine + polyethylene glycol

caution advised, especially if polyethylene glycol bowel prep use: combo may incr. risk of seizures (additive effects)

• polyethylene glycol/electrolytes
Tonmya (cyclobenzaprine)

+

polyethylene glycol/ electrolytes

1 interaction

Caution Advised

cyclobenzaprine + polyethylene glycol/ electrolytes

caution advised: combo may incr. risk of seizures (additive effects)

• potassium acid phosphate
Tonmya (cyclobenzaprine)

+

potassium acid phosphate

1 interaction

Caution Advised

cyclobenzaprine + potassium acid phosphate

caution advised w/ solid potassium formulations; liquid potassium formulations OK: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• potassium gluconate
Tonmya (cyclobenzaprine)

+

potassium gluconate

1 interaction

Caution Advised

cyclobenzaprine + potassium gluconate

caution advised w/ solid potassium formulations; liquid potassium formulations OK: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• potassium phosphate
Tonmya (cyclobenzaprine)

+

potassium phosphate

1 interaction

Caution Advised

cyclobenzaprine + potassium phosphate

caution advised w/ solid potassium formulations; liquid potassium formulations OK: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• pramipexole
Tonmya (cyclobenzaprine)

+

pramipexole

1 interaction

Caution Advised

cyclobenzaprine + pramipexole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• procainamide
Tonmya (cyclobenzaprine)

+

procainamide

1 interaction

Caution Advised

cyclobenzaprine + procainamide

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• prochlorperazine
Tonmya (cyclobenzaprine)

+

prochlorperazine

1 interaction

Caution Advised

cyclobenzaprine + prochlorperazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• pyridostigmine
Tonmya (cyclobenzaprine)

+

pyridostigmine

1 interaction

Caution Advised

cyclobenzaprine + pyridostigmine

caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

• pyrilamine
Tonmya (cyclobenzaprine)

+

pyrilamine

1 interaction

Caution Advised

cyclobenzaprine + pyrilamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• quetiapine
Tonmya (cyclobenzaprine)

+

quetiapine

1 interaction

Caution Advised

cyclobenzaprine + quetiapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects, incl. hyperthermia (additive effects)

• quinidine (antiarrhythmic)
Tonmya (cyclobenzaprine)

+

quinidine (antiarrhythmic)

1 interaction

Caution Advised

cyclobenzaprine + quinidine (antiarrhythmic)

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• quinidine (CYP2D6 inhibitor)
Tonmya (cyclobenzaprine)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Caution Advised

cyclobenzaprine + quinidine (CYP2D6 inhibitor)

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• ramelteon
Tonmya (cyclobenzaprine)

+

ramelteon

1 interaction

Caution Advised

cyclobenzaprine + ramelteon

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• repotrectinib
Tonmya (cyclobenzaprine)

+

repotrectinib

1 interaction

Caution Advised

cyclobenzaprine + repotrectinib

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• risperidone
Tonmya (cyclobenzaprine)

+

risperidone

1 interaction

Caution Advised

cyclobenzaprine + risperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• ritonavir
Tonmya (cyclobenzaprine)

+

ritonavir

1 interaction

Caution Advised

cyclobenzaprine + ritonavir

caution advised: combo may decr. cyclobenzaprine levels, efficacy (hepatic metab. induced)

• ropinirole
Tonmya (cyclobenzaprine)

+

ropinirole

1 interaction

Caution Advised

cyclobenzaprine + ropinirole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rotigotine transdermal
Tonmya (cyclobenzaprine)

+

rotigotine transdermal

1 interaction

Caution Advised

cyclobenzaprine + rotigotine transdermal

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rufinamide
Tonmya (cyclobenzaprine)

+

rufinamide

1 interaction

Caution Advised

cyclobenzaprine + rufinamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• scopolamine
Tonmya (cyclobenzaprine)

+

scopolamine

1 interaction

Caution Advised

cyclobenzaprine + scopolamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• selinexor
Tonmya (cyclobenzaprine)

+

selinexor

1 interaction

Caution Advised

cyclobenzaprine + selinexor

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sodium picosulfate
Tonmya (cyclobenzaprine)

+

sodium picosulfate

1 interaction

Caution Advised

cyclobenzaprine + sodium picosulfate

caution advised: combo may incr. risk of seizures (additive effects)

• solifenacin
Tonmya (cyclobenzaprine)

+

solifenacin

1 interaction

Caution Advised

cyclobenzaprine + solifenacin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• stiripentol
Tonmya (cyclobenzaprine)

+

stiripentol

1 interaction

Caution Advised

cyclobenzaprine + stiripentol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• sulfate bowel prep
Tonmya (cyclobenzaprine)

+

sulfate bowel prep

1 interaction

Caution Advised

cyclobenzaprine + sulfate bowel prep

caution advised: combo may incr. risk of seizures (additive effects)

• tasimelteon
Tonmya (cyclobenzaprine)

+

tasimelteon

1 interaction

Caution Advised

cyclobenzaprine + tasimelteon

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• temazepam
Tonmya (cyclobenzaprine)

+

temazepam

1 interaction

Caution Advised

cyclobenzaprine + temazepam

caution advised: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• tetrabenazine
Tonmya (cyclobenzaprine)

+

tetrabenazine

1 interaction

Caution Advised

cyclobenzaprine + tetrabenazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiotepa
Tonmya (cyclobenzaprine)

+

thiotepa

1 interaction

Caution Advised

cyclobenzaprine + thiotepa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tiagabine
Tonmya (cyclobenzaprine)

+

tiagabine

1 interaction

Caution Advised

cyclobenzaprine + tiagabine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• tiotropium inhaled
Tonmya (cyclobenzaprine)

+

tiotropium inhaled

1 interaction

Caution Advised

cyclobenzaprine + tiotropium inhaled

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• tizanidine
Tonmya (cyclobenzaprine)

+

tizanidine

1 interaction

Caution Advised

cyclobenzaprine + tizanidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolcapone
Tonmya (cyclobenzaprine)

+

tolcapone

1 interaction

Caution Advised

cyclobenzaprine + tolcapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolterodine
Tonmya (cyclobenzaprine)

+

tolterodine

1 interaction

Caution Advised

cyclobenzaprine + tolterodine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• topiramate
Tonmya (cyclobenzaprine)

+

topiramate

1 interaction

Caution Advised

cyclobenzaprine + topiramate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• treosulfan
Tonmya (cyclobenzaprine)

+

treosulfan

1 interaction

Caution Advised

cyclobenzaprine + treosulfan

caution advised: combo may incr. risk of seizures (additive effects)

• trifluoperazine
Tonmya (cyclobenzaprine)

+

trifluoperazine

1 interaction

Caution Advised

cyclobenzaprine + trifluoperazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• trihexyphenidyl
Tonmya (cyclobenzaprine)

+

trihexyphenidyl

1 interaction

Caution Advised

cyclobenzaprine + trihexyphenidyl

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, anticholinergic adverse effects (additive effects)

• triprolidine
Tonmya (cyclobenzaprine)

+

triprolidine

1 interaction

Caution Advised

cyclobenzaprine + triprolidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• tropicamide ophthalmic
Tonmya (cyclobenzaprine)

+

tropicamide ophthalmic

1 interaction

Caution Advised

cyclobenzaprine + tropicamide ophthalmic

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• trospium
Tonmya (cyclobenzaprine)

+

trospium

1 interaction

Caution Advised

cyclobenzaprine + trospium

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, anticholinergic adverse effects (additive effects)

• umeclidinium inhaled
Tonmya (cyclobenzaprine)

+

umeclidinium inhaled

1 interaction

Caution Advised

cyclobenzaprine + umeclidinium inhaled

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• valbenazine
Tonmya (cyclobenzaprine)

+

valbenazine

1 interaction

Caution Advised

cyclobenzaprine + valbenazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valerian
Tonmya (cyclobenzaprine)

+

valerian

1 interaction

Caution Advised

cyclobenzaprine + valerian

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valproic acid
Tonmya (cyclobenzaprine)

+

valproic acid

1 interaction

Caution Advised

cyclobenzaprine + valproic acid

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• vibegron
Tonmya (cyclobenzaprine)

+

vibegron

1 interaction

Caution Advised

cyclobenzaprine + vibegron

caution advised: combo may incr. risk of urinary retention (additive effects)

• vigabatrin
Tonmya (cyclobenzaprine)

+

vigabatrin

1 interaction

Caution Advised

cyclobenzaprine + vigabatrin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

• viloxazine
Tonmya (cyclobenzaprine)

+

viloxazine

1 interaction

Caution Advised

cyclobenzaprine + viloxazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zonisamide
Tonmya (cyclobenzaprine)

+

zonisamide

1 interaction

Caution Advised

cyclobenzaprine + zonisamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)